Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological Memory of GSK's 11-valent Pneumococcal Vaccine
NCT00169507Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2005
- Primary completion
- Apr 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of 11-valent pneumococcal conjugate vaccine in pneumococcal infection (2 arms), sponsored by GSK. Primary endpoint: Antibody concentrations (ELISA) to pneumococcal serotypes. Started Mar 2005; status: completed.
02
Drugs
11-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT00169507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00169507.